)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Neumora Therapeutics
Neumora Therapeutics (NMRA) investor relations material
Neumora Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary30 Mar, 2026
Executive summary
Achieved significant clinical and pipeline progress in 2025, advancing next-generation therapies for brain diseases and obesity.
Reported compelling NMRA-511 data in Alzheimer's agitation and advanced phase III Navacaprant studies for major depressive disorder.
Expanded M4 PAM franchise with NMRA-898 as lead for schizophrenia and prioritized NMRA-215 for obesity, supported by class-leading preclinical data.
Strong cash position of $182.5 million expected to fund operations into Q3 2027.
Entering 2026 with multiple anticipated clinical data readouts and value-creating milestones.
Financial highlights
Ended 2025 with $182.5 million in cash equivalents and marketable securities.
Q4 2025 R&D expenses were $44.7 million, down from $45.9 million in Q4 2024; full year R&D was $176.1 million, down from $200.9 million.
Q4 2025 G&A expenses were $13.8 million, down from $17.0 million in Q4 2024; full year G&A was $60.1 million, down from $62.5 million.
Net loss for 2025 was $236.9 million, compared to $243.8 million in 2024.
Net loss for 2025 was comparable to 2024.
Outlook and guidance
Cash runway expected to support operations into Q3 2027.
Multiple clinical data readouts expected in 2026, including NMRA-511 MAD extension and Navacaprant KOASTAL-2/3 phase III results.
NMRA-511 phase II study planned for Q1 2027; NMRA-215 clinical entry also targeted for Q1 2027.
NMRA-898 MAD study data in schizophrenia expected in H2 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Neumora Therapeutics
- Advancing novel therapies for brain and metabolic disorders with key milestones expected by 2027.NMRA
Corporate presentation30 Mar 2026 - NMRA-511 shows strong efficacy in Alzheimer's agitation; pipeline and funding support robust growth.NMRAGuggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026
- Advancing brain-penetrant therapies for obesity, Alzheimer's agitation, and psychiatric disorders.NMRACorporate presentation11 Feb 2026
- Navacaprant’s phase III COASTAL studies for MDD are on track, targeting robust efficacy and safety.NMRAStatus Update20 Jan 2026
- Pivotal Phase 3 data for navacaprant in MDD expected by year-end, with strong cash runway.NMRAQ3 202414 Jan 2026
- Navacaprant's phase 3 trials for MDD target key endpoints, with pivotal data due by 2025.NMRAGuggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026
- Key phase III MDD data expected by mid-2025, supporting a robust, expanding pipeline.NMRAStifel 2024 Healthcare Conference13 Jan 2026
- Multiple neuroscience programs advance with strong financials and key clinical readouts ahead.NMRA43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
- NMRA-511 showed strong efficacy and safety in Alzheimer's agitation, especially for anxious patients.NMRAStudy Result5 Jan 2026
Next Neumora Therapeutics earnings date
Q1 202611 May, 2026
Neumora Therapeutics
Next Neumora Therapeutics earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage